Display Settings:

Format

Send to:

Choose Destination
    Breast Cancer Res. 2005;7(4):153-62. Epub 2005 May 12.

    Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography.

    Source

    Metabolic and Functional Imaging Center, Clinical Research Center, Centre Hospitalier Universitaire de Sherbrooke, Fleurimont, QC, Canada. francois.benard@usherbrooke.ca

    Abstract

    Although mammography remains a key imaging method for the early detection and screening of breast cancer, the overall accuracy of this test remains low. Several radiopharmaceuticals have been proposed as adjunct imaging methods to characterize breast masses by single-photon-emission computed tomography (SPECT) and positron-emission tomography (PET). Useful in characterizing indeterminate palpable masses and in the detection of axillary metastases, these techniques are insufficiently sensitive to detect subcentimetric tumor deposits. Their role in staging nodal involvement of the axillary areas therefore currently remains limited. Several enzymes and receptors have been targeted for imaging breast cancers with PET. [18F]fluorodeoxyglucose is particularly useful in the detection and staging of recurrent breast cancer and in assessing the response to chemotherapy. Several other ligands targeting proliferative activity, protein synthesis, and hormone and cell-membrane receptors may complement this approach by providing unique information about biological characteristics of breast cancer across primary and metastatic tumor sites.

    PMID:
    15987467
    [PubMed - indexed for MEDLINE]
    PMCID: PMC1175073
    Free PMC Article

    Images from this publication.See all images (2) Free text

    Figure 1
    Figure 2

      Supplemental Content

      Click here to read Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk